Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 2/20 | 0.56 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.50 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | TNKS | O95271 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | AXIN2 | Q9Y2T1 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11068984 | 0.91 | OXTR (0.52) | OXTRAVPR1AAVPR2GAANPC1 | |
| SCHEMBL10012186 | 0.83 | OXTR (0.61) | OXTRAVPR1AAVPR2GLAHTT | |
| SCHEMBL13703856 | 0.81 | KDM4E (0.47) | OXTRAVPR1AGAATNKS2CYP2C9 | |
| SCHEMBL6402514 | 0.79 | OXTR (0.57) | OXTRAVPR1AAVPR2GLATNKS2 | |
| SCHEMBL12110672 | 0.79 | OXTR (0.69) | OXTRAVPR1AAVPR2GAAGLA | |
| SCHEMBL11384854 | 0.78 | TLR8 (0.44) | OXTRGAAGLACYP2C9CYP3A4 | |
| SCHEMBL12110605 | 0.78 | KDM4E (0.46) | AVPR1AGAAGLATNKS2NPC1 | |
| SCHEMBL11919913 | 0.78 | OXTR (0.52) | OXTRAVPR1AAVPR2GAAGLA | |
| SCHEMBL1562739 | 0.77 | AVPR1A (0.56) | OXTRAVPR1AGAAMAPK1HTT | |
| SCHEMBL6406225 | 0.77 | OXTR (0.55) | OXTRAVPR1AAVPR2GLAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011122815-A2 | NOVEL QUINOXALINE DERIVATIVES | DONG-A PHARM.CO.,LTD. (KR) | 2011-10-06 | — | — | WO | disclosed |
| US-20050288347-A1 | Certain triazole-based compounds, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2005-12-29 | — | — | US | disclosed |
| US-4268680-A | FUNGICIDES, BACTERICIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1981-05-19 | — | — | US | disclosed |
| US-4244964-A | FUNGICIDES, BACTERICIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1981-01-13 | — | — | US | disclosed |
| US-4232034-A | FUNGICIDES, BACTERICIDES | JANSSEN PHARMACEUTICA, N.V. (BE) | 1980-11-04 | — | — | US | disclosed |
| US-4229581-A | FUNGICIDES, BACTERICIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-10-21 | — | — | US | disclosed |
| US-4229460-A | FUNGICIDES, BACTERICIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-10-21 | — | — | US | disclosed |
| US-4160841-A | FUNGICIDES, BACTERICIDES | JANSSEN PHARMACEUTICA, N.V. (BE) | 1979-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288347-A1 | Certain triazole-based compounds, compositions, and uses thereof | ABCG2, ATP5ME, DNTT | OXTR 4696/4885AVPR1A 4869/4885AVPR2 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.